Results 131 to 140 of about 2,348 (179)

Sonidegib for basal cell carcinoma.

Australian prescriber
openaire   +1 more source

Expert opinion on sonidegib efficacy, safety and tolerability

Expert Opinion on Drug Safety, 2021
Introduction: Hedgehog inhibitors are an alternative treatment option for patients with advanced BCCs not eligible for standard therapies due to lack of efficacy, high recurrence risk, and high-rate morbidity.
Alessia Villani, Gabriella Fabbrocini, Sonia Sofia Ocampo-Garza   +2 more
exaly   +5 more sources

Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers

Cancer Chemotherapy and Pharmacology, 2014
Purpose: The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.
Markus Zollinger
exaly   +2 more sources

Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data [PDF]

Cancers, 2023
Basal cell carcinoma (BCC) represents the most common skin cancer and locally advanced BCC (laBCC) refers to an aggressive, large, infiltrative BCC that cannot be treated by surgery or radiotherapy.
Gianluca Nazzaro, Maria A Mattioli, Nerina Denaro   +2 more
exaly   +2 more sources

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma

Actas Dermo-sifiliográficas, 2021
Sonidegib is an antagonist of the transmembrane protein Smoothened in the Hedgehog signaling pathway. It is indicated for the treatment of locally advanced basal cell carcinoma (BCC) that is not amenable to curative surgery or radiotherapy. Sonidegib's efficacy and safety were demonstrated in the phase 2 BOLT trial, where 61% (95% CI, 48-72%) of ...
B Llombart, Rafael Botella-Estrada, Susana Puig   +2 more
exaly   +4 more sources

Improving the Antitumor Activity and Bioavailability of Sonidegib for the Treatment of Skin Cancer [PDF]

Pharmaceutics, 2021
Throughout the United States and the world, skin cancer is the most frequent form of cancer. Sonidegib (SNG) is a hedgehog inhibitor that has been used for skin cancer treatment. However, SNG has low bioavailability and is associated with resistance.
Salem Heba F, Haitham Saeed, Fatma I Abo El-Ela   +2 more
exaly   +4 more sources

Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas

OncoTargets and Therapy, 2017
The Hedgehog (Hh) pathway is critical for cell differentiation, tissue polarity, and stem cell maintenance during embryonic development, but is silent in adult tissues under normal conditions. However, aberrant Hh signaling activation has been implicated
Sachin Jain, Jingwu Xie
exaly   +3 more sources

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors

Investigational New Drugs, 2017
Purpose To establish a recommended phase II dose (RP2D) for the oral smoothened inhibitor sonidegib in combination with paclitaxel; secondary objectives include evaluation of safety, tolerability, markers of Hedgehog (Hh) signaling and preliminary ...
Anastasios Stathis, D Hes, K Homicsko
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Sonidegib for the Treatment of Advanced Basal Cell Carcinoma: A Comprehensive Review of Sonidegib and the Bolt Trial with 12-Month Update

Future Oncology, 2016
The Hedgehog inhibitors are promising alternative for patients with advanced basal cell carcinoma that are not amenable to radiotherapy or surgery. Sonidegib, also known as LDE225, is an orally available SMO antagonist that was recently approved by the US FDA for the treatment of patients with locally advanced basal cell carcinoma.
Sirunya Silapunt
exaly   +3 more sources